Pharmacy Receipt According to the FTC’s antitrust analysis, competition between manufacturers to drive their drug’s utilization “can become a ‘trap’ for payers and providers.” (Photo: Shutterstock)

There has been a strong emphasis on savings derived from manufacturer rebates, but the Federal Trade Commission’s May 2021 report on rebate walls suggests that all that glitters isn’t gold: a focus on driving rebates can distract from the goal of reducing overall net plan costs. For the best outcomes, a strategy to reduce drug spend should include a balanced review of rebate transparency, drug utilization, and plan design.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.